The present invention provides a compound of formula (I): ##STR00001##
said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

The invention generally relates to a process for preparing compounds, including Compound of Formula (I), useful as key intermediates in the preparation of compounds having RORγt antagonist properties.

##STR00001##

The invention relates to an organic ammonium salt of formula (I), wherein the symbols have the following meanings: A- is an anionic pesticide, R.sup.1 is H, C.sub.1C.sub.4-alkyl, CH.sub.2CH.sub.2OH or CH.sub.2CH(CH.sub.3)OH; R is H, CH.sub.3 or two adjacent radicals R together form a group —C(R′)— and R′ is equal to or different from H or CH.sub.3, wherein said salt is suitable for reducing the volatility of active substances in the spray application of anionic pesticides.

##STR00001##

The invention relates to an organic ammonium salt of formula (I), wherein the symbols have the following meanings: A- is an anionic pesticide, R.sup.1 is H, C.sub.1C.sub.4-alkyl, CH.sub.2CH.sub.2OH or CH.sub.2CH(CH.sub.3)OH; R is H, CH.sub.3 or two adjacent radicals R together form a group —C(R′)— and R′ is equal to or different from H or CH.sub.3, wherein said salt is suitable for reducing the volatility of active substances in the spray application of anionic pesticides.

##STR00001##

The present disclosure relates to HIF-2α inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2α scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo.

In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.

In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL patients, such as those with substantial cardiac involvement who have difficulty tolerating existing chemotherapy regimens, provided herein are small molecule compounds of Formula Ia, Formula Ib, and Formula II that are kinetic stabilizers of the native dimeric structure of full-length LCs, which compounds can slow or stop the amyloidogenicity cascade at its origin.

The present disclosure relates to methods of carbon-carbon bond fragmentation.

The present disclosure relates to methods of carbon-carbon bond fragmentation.

The present application relates to compounds and methods for reducing the severity of convulsant activity or epileptic seizures, or for the treatment of chronic or acute pain.